Home

Latest News

12345678910
Sable Offshore Corp (NYSE:SOC) Reports Q3 2025 Results with No Revenue, Wider Losschartmill.com
Sable Offshore (SOC) Q3 2025 results show no revenue, a wider-than-expected loss, and operational hurdles delaying oil sales from its Santa Ynez Unit.
Via Chartmill · November 13, 2025
The Glimpse Group (VRAR) Q1 FY2026 Earnings Miss Revenue Estimateschartmill.com
The Glimpse Group (VRAR) Q1 FY2026 revenue missed estimates, but its EPS loss was slightly better than expected. The company is focused on its Brightline Interactive spinoff and new government contracts.
Via Chartmill · November 13, 2025
Vinci Compass Investments Ltd (NASDAQ:VINP) Posts Q3 2025 Earnings Beat Amid Revenue Misschartmill.com
Vinci Compass (VINP) posts mixed Q3 2025 results, beating EPS estimates with $1.17 but missing on revenue. The stock rose on the profit beat.
Via Chartmill · November 13, 2025
Alpha Cognition Inc. (NASDAQ:ACOG) Reports Q3 2025 Revenue Beat and Strong Commercial Progress for ZUNVEYLchartmill.com
Alpha Cognition's Q3 2025 results beat revenue estimates by 37% on strong sales of its Alzheimer's drug, ZUNVEYL, showing significant commercial momentum.
Via Chartmill · November 13, 2025
The Oncology Institute (NASDAQ:TOI) Surpasses Revenue Estimates and Raises 2025 Guidance Despite Wider Q3 Losschartmill.com
Oncology Institute (TOI) beat Q3 2025 revenue forecasts and raised its full-year guidance, driving a 17.5% stock surge despite a wider quarterly loss.
Via Chartmill · November 13, 2025
Relmada Therapeutics Inc (NASDAQ:RLMD) Reports Wider-Than-Expected Q3 2025 Losschartmill.com
Relmada Therapeutics posts a wider-than-expected Q3 2025 loss, but reports strong 92% response rate for its bladder cancer drug NDV-01.
Via Chartmill · November 13, 2025
Senti Biosciences Inc (NASDAQ:SNTI) Q3 2025 Earnings Miss Estimates, Stock Falls on Revenue and EPS Shortfallchartmill.com
Senti Bio missed Q3 2025 earnings and revenue estimates, but eyes a key catalyst with upcoming Phase 1 AML data at the ASH meeting.
Via Chartmill · November 13, 2025
Legacy Education Inc (NYSEARCA:LGCY) Reports Q1 2026 Revenue Beat Driven by Enrollment Growthchartmill.com
Legacy Education (LGCY) Q1 2026 earnings beat revenue estimates with strong growth driven by a surge in student enrollment.
Via Chartmill · November 13, 2025
Gold Price Forecast: XAU/USD Climbs Above $4,150 As US Shutdown Endscontent/com
Gold price (XAU/USD) trades in positive territory near $4,185 during the early Asian session on Friday.
Via Talk Markets · November 13, 2025
AirJoule Technologies Corp (NASDAQ:AIRJ) Posts Narrower-Than-Expected Q3 2025 Loss, Stock Riseschartmill.com
AirJoule (AIRJ) stock rose after Q3 2025 results, beating EPS estimates with a smaller loss. The water-harvesting tech firm also announced key partnerships and progress toward 2026 commercialization.
Via Chartmill · November 13, 2025
Innventure Inc. (NASDAQ:INV) Reports Q3 2025 Revenue Miss and Widening Losseschartmill.com
Innventure Q3 2025 results show a major revenue miss and a wider-than-expected loss, causing shares to drop nearly 10% despite strategic progress.
Via Chartmill · November 13, 2025
TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Q3 2025 Results with Strong Revenue Growth but Significant EPS Misschartmill.com
TriSalus Q3 2025 results show strong 57% revenue growth but a wider-than-expected EPS loss. The company reaffirmed its 50% full-year growth outlook.
Via Chartmill · November 13, 2025
BLAIZE HOLDINGS INC (NASDAQ:BZAI) Surpasses Q3 2025 Revenue Estimates and Narrows Losschartmill.com
Blaize Holdings (BZAI) beat Q3 2025 revenue and EPS estimates, showing strong growth and progress on its path toward profitability.
Via Chartmill · November 13, 2025
Applied Materials Inc (NASDAQ:AMAT) Reports Q4 FY 2025 Earnings, Beats Estimateschartmill.com
Applied Materials (AMAT) narrowly beat Q4 FY2025 earnings and revenue estimates, achieving record annual results driven by AI and advanced semiconductor demand.
Via Chartmill · November 13, 2025
Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Planschartmill.com
Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.
Via Chartmill · November 13, 2025
Precigen Inc (NASDAQ:PGEN) Q3 2025 Earnings: Revenue Soars But Wider Loss Dampens Investor Sentimentchartmill.com
Precigen's Q3 2025 results show a huge revenue beat but a wider-than-expected loss. The key highlight is the full FDA approval and launch of its new therapy, PAPZIMEOS.
Via Chartmill · November 13, 2025
Hyperfine Inc (NASDAQ:HYPR) Reports Mixed Q3 2025 Results, Provides Q4 Outlookchartmill.com
Hyperfine (HYPR) reported mixed Q3 2025 results, missing revenue and EPS estimates. The stock fell as its Q4 revenue guidance also trailed analyst expectations.
Via Chartmill · November 13, 2025
Vaxart Inc (NASDAQ:VXRT) Surges on Stellar Q3 2025 Earnings and $700M Dynavax Dealchartmill.com
Vaxart stock surges after Q3 earnings crush estimates and a major $700M licensing deal with Dynavax for its oral COVID-19 vaccine candidate.
Via Chartmill · November 13, 2025
CaliberCos Inc. (NASDAQ:CWD) Reports Steep Q3 2025 Loss, Missing EPS Estimates by Over 400%chartmill.com
CaliberCos (CWD) missed Q3 2025 EPS and revenue estimates, posting a larger-than-expected loss. The stock declined as a result.
Via Chartmill · November 13, 2025
Net Power Inc (NYSE:NPWR) Plunges 12% on Strategic Pivot Despite EPS Beatchartmill.com
Net Power stock fell 12% after a strategic pivot to carbon capture tech, overshadowing an accounting-driven EPS beat and revealing a major asset impairment.
Via Chartmill · November 13, 2025
Why Spectrum Brands Stock Rocked the Market on Thursdayfool.com
The company blasted past analyst estimates for profitability in its most recently completed quarter.
Via The Motley Fool · November 13, 2025
HeartBeam Inc (NASDAQ:BEAT) Reports Q3 2025 Earnings Miss, Focuses on Key FDA Clearancechartmill.com
HeartBeam reports Q3 2025 results, missing EPS estimates. The pre-revenue firm focuses on FDA clearance for its cardiac tech, a key milestone expected by year-end.
Via Chartmill · November 13, 2025
BioAtla Inc (NASDAQ:BCAB) Reports Narrower-Than-Expected Q3 2025 Losschartmill.com
BioAtla (BCAB) beat Q3 2025 EPS estimates, sending its stock up 7.5%. The biotech also gained FDA alignment for its Phase 3 trial in head and neck cancer.
Via Chartmill · November 13, 2025
TELA Bio Inc (NASDAQ:TELA) Reports Mixed Q3 2025 Results, Misses Revenue Estimateschartmill.com
TELA Bio reports Q3 2025 results with 9% revenue growth to $20.7M, missing estimates. The company improved its net loss and secured new financing for future expansion.
Via Chartmill · November 13, 2025
Rekor Systems Inc (NASDAQ:REKR) Posts Record Q3 2025, Beating Revenue and EPS Estimateschartmill.com
Rekor Systems (REKR) smashed Q3 2025 estimates with record revenue of $14.2M and a smaller-than-expected loss, sparking a positive after-hours market reaction.
Via Chartmill · November 13, 2025
Wolf Hill Nearly Liquidates $78 Million Shift4 Payments Stake: Is the Stock in Trouble?fool.com
Wolf Hill Nearly Liquidates $78 Million Shift4 Payments Stake: Is the Stock in Trouble?
Via The Motley Fool · November 13, 2025
CO-DIAGNOSTICS INC (NASDAQ:CODX) Reports Q3 2025 Results, Missing Revenue Estimateschartmill.com
Co-Diagnostics (CODX) reported mixed Q3 2025 results, beating EPS estimates but missing on revenue. The stock fell over 4% after-hours.
Via Chartmill · November 13, 2025
PIONEER POWER SOLUTIONS INC (NASDAQ:PPSI) Reports Mixed Q3 2025 Resultschartmill.com
Pioneer Power (PPSI) reported Q3 2025 revenue growth, beating estimates, but faces profitability challenges with widening losses.
Via Chartmill · November 13, 2025
Vuzix Corp (NASDAQ:VUZI) Reports Q3 2025 Revenue Miss Amid Strategic Moveschartmill.com
Vuzix Q3 2025 earnings miss revenue estimates, causing a stock dip. The company also secures a $5M investment and appoints a new enterprise president.
Via Chartmill · November 13, 2025
WidePoint Corp (NYSEARCA:WYY) Reports Mixed Q3 2025 Results with Strong Contract Wins and Sequential Profitability Growthchartmill.com
WidePoint's Q3 2025 earnings show a revenue miss but strong sequential profit growth. The company secured major new contracts and maintains a $269M backlog for future growth.
Via Chartmill · November 13, 2025
Research Solutions Inc (NASDAQ:RSSS) Reports Mixed Q1 2026 Results with Strong ARR Growthchartmill.com
Research Solutions (RSSS) posts mixed Q1 2026 results, missing revenue estimates but showing strong 21% growth in Annual Recurring Revenue and improved profitability.
Via Chartmill · November 13, 2025
Cytosorbents Corp (NASDAQ:CTSO) Posts Mixed Q3 2025 Results Amidst Stock Volatilitychartmill.com
Cytosorbents Q3 2025 earnings show a mixed quarter, beating EPS estimates but missing on revenue. The stock saw volatility despite a strengthened balance sheet.
Via Chartmill · November 13, 2025
EVOLV TECHNOLOGIES HOLDINGS (NASDAQ:EVLV) Delivers Strong Q3 Beat and Raises Full-Year Guidancechartmill.com
Evolv Technology (EVLV) crushed Q3 2025 earnings estimates, reporting a surprise profit and strong revenue growth. The company also raised its full-year guidance.
Via Chartmill · November 13, 2025
Cibus Inc (NASDAQ:CBUS) Reports Q3 2025 Earnings Miss on Revenue, Narrower Losschartmill.com
Cibus (CBUS) Q3 2025 results show a narrower loss but a revenue miss, sending shares lower. The company highlights progress on key rice traits and cost-saving initiatives.
Via Chartmill · November 13, 2025
JEFFERSON CAPITAL INC (NASDAQ:JCAP) Tops Q3 2025 Earnings and Revenue Estimateschartmill.com
Jefferson Capital (JCAP) beat Q3 2025 earnings and revenue estimates, driven by record collections and deployments. The company also announced a major acquisition.
Via Chartmill · November 13, 2025
CapsoVision Inc (NASDAQ:CV) Misses Q3 2025 Earnings and Revenue Estimateschartmill.com
CapsoVision (CV) missed Q3 2025 earnings and revenue estimates. The medical tech firm posted a wider-than-expected loss per share and lower sales.
Via Chartmill · November 13, 2025
Nu Holdings Ltd. (NYSE:NU) Q3 2025 Earnings: Revenue and EPS Top Estimateschartmill.com
Nu Holdings (NU) Q3 2025 earnings smashed revenue estimates, reporting $4.17B. Customer growth and profitability surged, driving a 39% YoY net income increase to $783M.
Via Chartmill · November 13, 2025
GBP/USD Bulls Struggle As UK Tax Plans And Weak Data Weightalkmarkets.com
GBP/USD caught a brief bullish slant to Thursday’s trading window, with Cable traders brushing off a worse-than-expected GDP growth print from the third quarter.
Via Talk Markets · November 13, 2025
MSC Income Fund Inc (NYSE:MSIF) Reports Mixed Q3 2025 Results, Beats on EPS but Misses on Revenuechartmill.com
MSC Income Fund (MSIF) reported mixed Q3 2025 results, beating EPS estimates but missing on revenue. The stock showed a cautious market reaction.
Via Chartmill · November 13, 2025
Aytu BioPharma Inc (NASDAQ:AYTU) Reports Q1 2026 Revenue Beat and Progress on EXXUA Launchchartmill.com
Aytu BioPharma posts Q1 revenue beat and narrows loss, fueling investor optimism for its upcoming EXXUA depression drug launch.
Via Chartmill · November 13, 2025
Luminar Technologies Inc (NASDAQ:LAZR) Reports Q3 2025 Earnings Beat and Strategic Review Amid Losseschartmill.com
Luminar (LAZR) Q3 2025 earnings beat revenue and EPS estimates, sending shares up 14%. The company is exploring strategic alternatives amid significant losses.
Via Chartmill · November 13, 2025
Origin Materials Inc (NASDAQ:ORGN) Reports Q3 2025 Earnings Miss and Negative Market Reactionchartmill.com
Origin Materials Q3 2025 results missed revenue and EPS estimates, causing a negative market reaction. The company maintains its long-term growth targets.
Via Chartmill · November 13, 2025
Spero Therapeutics Inc (NASDAQ:SPRO) Posts Q3 Revenue and EPS Beatchartmill.com
Spero Therapeutics (SPRO) smashed Q3 2025 earnings, with revenue of $5.44M beating $0 estimates and a narrower EPS loss of -$0.13.
Via Chartmill · November 13, 2025
Perfect Moment Ltd (NYSEARCA:PMNT) Reports Strong Q2 Revenue Beat and Narrows Loss on Path to Profitabilitychartmill.com
Perfect Moment's Q2 earnings beat revenue forecasts, slashing losses by over 50% as its wholesale strategy drives growth and margin expansion.
Via Chartmill · November 13, 2025
This ‘Strong Buy’ Dividend Stock Yields 8%. Should You Add It to Your Portfolio?
The company currently offers a high dividend yield of about 8%, backed by a consistent track record of dividend growth and a “Strong Buy” consensus from Wall Street analysts.
Via Barchart.com · November 13, 2025
Stocks Waver Ahead Of Holidays… Will Santa Arrive As Scheduled?talkmarkets.com
Stocks can’t go straight up forever, and this bull run has become long in the tooth.
Via Talk Markets · November 13, 2025
AI Frenzy: Everybody Wants Nvidia's Magical GPUstalkmarkets.com
​​​​​​​The AI frenzy continues to dominate headlines, with poster child Nvidia at the forefront of conversations.
Via Talk Markets · November 13, 2025
SentinelOne: A Stock Analysis Amid Fierce Cybersecurity Competitionfool.com
Join us as we dissect SentinelOne's stock performance and future potential in the competitive cybersecurity landscape. Can its new AI product turn the tide?
Via The Motley Fool · November 13, 2025
The Tech Gods Blinktalkmarkets.com
A mass de-risking ritual the street performs whenever liquidity thins, uncertainty thickens, and everyone wants to pretend they’re early rather than late.
Via Talk Markets · November 13, 2025
TradFi Meets Crypto: Stablecoins, Speed — And The New Market Orderbenzinga.com
The intersection of TradFi and crypto is reshaping finance, as revealed in a panel discussion at the Benzinga Fintech Day & Awards 2025.
Via Benzinga · November 13, 2025